Google
SPRO — SPERO THERAPEUTICS INC (Healthcare >> Biotechnology)
SPRO FAQ
What is SPRO's P/E ratio?
SPERO THERAPEUTICS INC (SPRO) currently trades at a P/E ratio of 5.18.
What is SPRO's ROE?
SPERO THERAPEUTICS INC reports a Return on Equity (ROE) of 28.78%.
What is SPRO's dividend yield?
SPERO THERAPEUTICS INC offers a dividend yield of 0.00%.
What is SPRO's Deepscope Quality Score?
Deepscope rates SPRO's overall financial quality at 62 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy SPRO?
Deepscope's AI Timing Score for SPRO is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does SPRO belong to?
SPERO THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 2.82
Price
-0.16
(-5.37%)
Day Change
|
|
|---|
SPRO, ファンダメンタルスコアはok ( ファンダメンタル = 62) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
ROEの伸びが低い
平均ROEが低い
ROAの伸びが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not quite good , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
55% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 96 |
| Magic Formula Rank by ROA |
147
|
| Magic Formula Rank by ROE |
147
|
| Magic Formula Rank by ROIC |
67
GOOD
|
| Price | 2.82 |
| PBV / Sector |
3.08 / 4.63
|
| Earning Per Share | 0.26 |
| PE / Sector |
5.18 / 17.43
GREAT
|
| PEG or PE/Growth / Sector |
-0.02 / 0.53
|
| Average 1M Daily Value |
2.23 M
GREAT
|
| Average 1W Daily Value |
2.17 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
60% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-06 09:09:21 |
| Symbol | SPRO |
| Name | SPERO THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 57.90 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 163.28 / 8,857.28 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 675 Massachusetts Avenue, Cambridge, MA, United States, 02139
Phone: 857 242 1600
Website: https://sperotherapeutics.com
Sector: Healthcare >> Biotechnology
Description: Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
